Question
To ask the Scottish Government, further to the answer to question S6W-13815 by Humza Yousaf on 24 January 2023, whether Palforzia will be approved as a treatment for peanut allergies through the NHS.
S6W-32433 · Written Question · lodged by Burnett, Alexander
Lodged on
17 Dec 2024Heard / answered on
24 Dec 2024To ask the Scottish Government, further to the answer to question S6W-13815 by Humza Yousaf on 24 January 2023, whether Palforzia will be approved as a treatment for peanut allergies through the NHS.
The answer
Aimmune Therapeutics, the manufacturer of Palforzia®, had indicated an intention to make a resubmission to the Scottish Medicines Consortium (SMC), however to date this has not been received. The decision on whether to submit, and the timing of that submission, is entirely for the manufacturer of the medicine to make. If they do resubmit, information on the specific timelines for the reassessment will be available via the search facility available on the home page of the SMC’s website here. There is a fast-track resubmission option, which reduces the normal assessment timeline.In the meantime, Health Boards have procedures in place using the Peer Approved Clinical System “PACS Tier Two” process, for clinicians to request the use of licensed medicines on a ‘case-by-case’ basis for individual patients, when the treating clinician considers that there would be significant clinical benefit for a patient.
Answered by Neil Gray on 24 Dec 2024.